IDIX Key Stats
- Idenix Pharmaceuticals' CEO Presents at UBS Global Healthcare Services Conferenc... May 21
- Idenix Pharmaceuticals' CEO Presents at Bank of America Merrill Lynch Health Car... May 15
- Seth Klarman's Worst Performing Stock Picks Year-To-Date May 13
- Idenix Pharmaceuticals to Present at Three Upcoming Healthcare Conferences GlobeNewswire May 8
- Gilead Misses Analysts’ Estimates on Sales of HIV Drugs May 2
- Vertex (VRTX) VX-135 Looks Interesting, Thinks Deutsche Bank Street Insider May 2
- Idenix Pharmaceuticals Reports First Quarter 2013 Financial Results noodls Apr 30
- IDENIX PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Apr 30
- IDENIX PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financi... Apr 30
- FDA Approvals Accelerate and Opportunities Arise in Hepatitis C Market: A Wall S... Apr 29
IDIX Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Idenix Pharmaceuticals is down 57.24% over the last year vs S&P 500 Total Return up 27.96%, Achillion Pharmaceuticals up 3.55%, and Vertex Pharmaceuticals up 22.52%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Pro Ratings for IDIX
Pro Report PDF for IDIX
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download IDIX Pro Report PDF
Pro Strategies Featuring IDIX
Did Idenix Pharmaceuticals make it into our Pro Portfolio Strategies?